Drug Profile
Research programme: transdermal carbohydrate macromolecules - Altea Therapeutics
Latest Information Update: 15 Nov 2012
Price :
$50
*
At a glance
- Originator Unknown
- Developer Altea Therapeutics
- Class Carbohydrates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Blood coagulation disorders